Last updated on January 2020

Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Thyroid Adenoma
  • Age: - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. All participants with unresectable thyroid cancer and administrated Lenvatinib.

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.